D-PHENYLALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-VALYL-L-CYSTEINYL-L-TRYPTOPHANAMIDE CYCLIC (2->7)-DISULFIDE
Portal Hypertension
Debiovisionprotein_peptidePhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the Portal Hypertension cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CARVEDILOL West China Hospital | Phase 4 | BBB |
SIMVASTATIN Kafrelsheikh University | Phase 4 | BBB |
PROPRANOLOL West China Hospital | Phase 4 | BBB |
Apixaban Asian Institute Of Medical Sciences | Phase 4 | BB |
Acetylsalicylic Acid Northern Jiangsu People's Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
D-PHENYLALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-VALYL-L-CYSTEINYL-L-TRYPTOPHANAMIDE CYCLIC (2->7)-DISULFIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →